Mann Devin, Reynolds Kristi, Smith Donald, Muntner Paul
Mount Sinai School of Medicine, New York, NY 10029, USA.
Ann Pharmacother. 2008 Sep;42(9):1208-15. doi: 10.1345/aph.1L181. Epub 2008 Jul 22.
Few data are available on the use of statins after publication of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) guidelines in 2001.
To determine changes in statin use and its impact on low-density lipoprotein cholesterol (LDL-C) control among US adults from 1999 to 2004.
High LDL-C levels and statin use among 1911 participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2004 were determined and compared with 1770 and 2094 participants of NHANES 1999-2000 and NHANES 2001-2002, respectively. Statin use was obtained from review of participants' drug containers. High LDL-C levels and LDL-C control were defined, using risk-specific cut-points from the ATP-III guidelines.
Statins were taken by 24 million Americans in 2003-2004, an increase from 12.5 million in 1999-2000. In 1999-2000, 2001-2002, and 2003-2004, statins were being used by 19.6%, 27.3%, and 35.9% of US adults with high LDL-C levels, respectively (p trend <0.001). Age-standardized mean LDL-C declined from 119.9 to 112.0 to 100.7 mg/dL among statin users between 1999-2000, 2001-2002, and 2003-2004. LDL-C control to ATP-III recommended targets was achieved by 49.7%, 67.4%, and 77.6% of statin users in 1999-2000, 2001-2002, and 2003-2004, respectively (p trend <0.001). Among US adults with high LDL-C, after multivariate adjustment, non-Hispanic blacks were 39% less likely (prevalence ratio = 0.61; 95 CI 0.39 to 0.97) than non-Hispanic whites to be taking statins.
Statin use continues to increase among US adults and this has led to substantial improvements in LDL-C control. Nevertheless, suboptimal statin use, especially among racial/ethnic minorities, continues to prevent the maximal public health benefit from this effective drug class.
2001年美国国家胆固醇教育计划第三次成人治疗专家组(ATP-III)指南发布后,关于他汀类药物使用的数据较少。
确定1999年至2004年美国成年人中他汀类药物使用情况的变化及其对低密度脂蛋白胆固醇(LDL-C)控制的影响。
确定了2003 - 2004年美国国家健康与营养检查调查(NHANES)1911名参与者的高LDL-C水平和他汀类药物使用情况,并分别与1999 - 2000年NHANES的1770名参与者和2001 - 2002年NHANES的2094名参与者进行比较。他汀类药物的使用情况通过检查参与者的药盒获得。根据ATP-III指南中特定风险的切点定义高LDL-C水平和LDL-C控制情况。
2003 - 2004年有2400万美国人服用他汀类药物,高于1999 - 2000年的1250万。在1999 - 2000年、2001 - 2002年和2003 - 2004年,LDL-C水平高的美国成年人中分别有19.6%、27.3%和35.9%使用他汀类药物(p趋势<0.001)。在1999 - 2000年、2001 - 2002年和2003 - 2004年期间,他汀类药物使用者的年龄标准化平均LDL-C水平分别从119.9降至112.0再降至100.7mg/dL。1999 - 2000年、2001 - 2002年和2003 - 2004年分别有49.7%、67.4%和77.6%的他汀类药物使用者将LDL-C控制在ATP-III推荐的目标水平(p趋势<0.001)。在美国LDL-C水平高的成年人中,经过多变量调整后,非西班牙裔黑人服用他汀类药物的可能性比非西班牙裔白人低39%(患病率比=0.61;95%置信区间0.39至0.97)。
美国成年人中他汀类药物的使用持续增加,这已使LDL-C控制有了显著改善。然而,他汀类药物使用不充分,尤其是在少数种族/族裔中,继续阻碍了这类有效药物实现最大的公共卫生效益。